243 related articles for article (PubMed ID: 37459099)
21. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.
Harris MH; DuBois SG; Glade Bender JL; Kim A; Crompton BD; Parker E; Dumont IP; Hong AL; Guo D; Church A; Stegmaier K; Roberts CWM; Shusterman S; London WB; MacConaill LE; Lindeman NI; Diller L; Rodriguez-Galindo C; Janeway KA
JAMA Oncol; 2016 May; 2(5):608-615. PubMed ID: 26822149
[TBL] [Abstract][Full Text] [Related]
22. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
[TBL] [Abstract][Full Text] [Related]
24. Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies.
Matsuo M; Hashimoto K; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
In Vivo; 2023; 37(5):2147-2154. PubMed ID: 37652518
[TBL] [Abstract][Full Text] [Related]
25. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
26. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
[TBL] [Abstract][Full Text] [Related]
27. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
[TBL] [Abstract][Full Text] [Related]
28. Clinical Outcomes of Comprehensive Genomic Profiling Tests for Gastrointestinal Cancers: Experience from Tokushima University Hospital.
Sato Y; Okada Y; Fujino Y; Kawaguchi T; Kida Y; Mitsui Y; Tanaka H; Tomonari T; Kitamura S; Okamoto K; Kawano Y; Miyamoto H; Sogabe M; Takayama T
J Med Invest; 2023; 70(1.2):154-159. PubMed ID: 37164713
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
30. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
Boscolo Bielo L; Belli C; Crimini E; Repetto M; Ascione L; Pellizzari G; Santoro C; Fuorivia V; Barberis M; Fusco N; Rocco EG; Curigliano G
Oncologist; 2024 Jun; 29(6):504-510. PubMed ID: 38520742
[TBL] [Abstract][Full Text] [Related]
31. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N
Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626
[TBL] [Abstract][Full Text] [Related]
32. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhan J; Zhao X; Chen X; Xiao L; Wu K; Ma Y; Li M; Yang Y; Fang W; Zhao H; Zhang L
BMC Med; 2021 Oct; 19(1):223. PubMed ID: 34592968
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.
Sivakumar S; Lee JK; Moore JA; Hopkins J; Newberg JY; Madison R; Graf R; Schrock AB; Kobetz E; Vince R; Franco I; Seldon C; Frampton GM; Mills J; Venstrom J; Mahal BA
Lancet Digit Health; 2023 Jun; 5(6):e380-e389. PubMed ID: 37236698
[TBL] [Abstract][Full Text] [Related]
34. Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience.
Seet AOL; Tan AC; Tan TJ; Ng MCH; Tai DWM; Lam JYC; Tan GS; Gogna A; Too CW; Tan BS; Takano A; Lim A; Lim TH; Lim ST; Dent RA; Ang MK; Yap YS; Tan IBH; Choo SP; Toh CK; Lim EH; Farid M; Skanderup AJ; Iyer NG; Lim WT; Tan EH; Lim TKH; Tan DSW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250396
[TBL] [Abstract][Full Text] [Related]
35. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
[TBL] [Abstract][Full Text] [Related]
37. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
38. Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice.
Čerina D; Matković V; Katić K; Lovasić IB; Šeparović R; Canjko I; Jakšić B; Fröbe A; Pleština S; Bajić Ž; Vrdoljak E
Pathol Oncol Res; 2021; 27():1609963. PubMed ID: 34646088
[TBL] [Abstract][Full Text] [Related]
39. Genomics driven precision oncology in advanced biliary tract cancer improves survival.
Kumar-Sinha C; Vats P; Tran N; Robinson DR; Gunchick V; Wu YM; Cao X; Ning Y; Wang R; Rabban E; Bell J; Shankar S; Mannan R; Zhang Y; Zalupski MM; Chinnaiyan AM; Sahai V
Neoplasia; 2023 Aug; 42():100910. PubMed ID: 37267699
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.
Weinberg BA; Gowen K; Lee TK; Ou SI; Bristow R; Krill L; Almira-Suarez MI; Ali SM; Miller VA; Liu SV; Klempner SJ
Oncologist; 2017 Feb; 22(2):152-157. PubMed ID: 28193735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]